Septerna, Inc. Common Stock (SEPN)

Price$31.15

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-0.59%

Price vs S&P 500 (4W)30.51%

VGM Score72.68

Market Capitalization$1.40B

All Metrics

P/CF (Annual)12.74x

Book Value / Share (Quarterly)$8.43

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$2.38

Price vs S&P 500 (YTD)3.57%

Net Profit Margin (TTM)-49.88%

EPS (TTM)$-0.82

10-Day Avg Trading Volume0.31M

EPS Excl Extra (TTM)$-0.82

EPS (Annual)$-1.10

ROI (Annual)-12.80%

Cash / Share (Quarterly)$7.73

Revenue Growth QoQ (YoY)12010.96%

ROA (Last FY)-8.20%

Revenue Growth TTM (YoY)11790.11%

EBITD / Share (TTM)$-1.21

Operating Margin (TTM)-77.07%

Cash Flow / Share (Annual)$2.45

P/B Ratio3.71x

P/B Ratio (Quarterly)2.85x

Net Income / Employee (Annual)$-376,000

EV / Revenue (TTM)18.44x

ROA (TTM)-6.59%

EPS Incl Extra (Annual)$-1.10

Current Ratio (Annual)4.73x

Quick Ratio (Quarterly)4.63x

3-Month Avg Trading Volume0.32M

52-Week Price Return196.10%

EV / Free Cash Flow (Annual)12.15x

Revenue / Employee (TTM)$555,800

P/S Ratio (Annual)30.56x

Asset Turnover (Annual)0.08x

52-Week High$32.63

EPS Excl Extra (Annual)$-1.10

26-Week Price Return7.34%

Quick Ratio (Annual)4.67x

13-Week Price Return13.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.71x

Enterprise Value$1.33B

Asset Turnover (TTM)0.13x

Revenue / Employee (Annual)$353,500

Pretax Margin (Annual)-106.35%

Cash / Share (Annual)$8.73

3-Month Return Std Dev58.93%

Net Income / Employee (TTM)$-277,200

ROE (Last FY)-12.80%

EPS Basic Excl Extra (Annual)$-1.10

Receivables Turnover (TTM)13.03x

EV / Free Cash Flow (TTM)12.46x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.82

Receivables Turnover (Annual)8.73x

ROI (TTM)-9.44%

P/S Ratio (TTM)19.43x

Revenue / Share (Annual)$1.04

Price vs S&P 500 (52W)171.74%

Year-to-Date Return11.73%

5-Day Price Return3.90%

EPS Normalized (Annual)$-1.10

Net Profit Margin (Annual)-106.37%

Month-to-Date Return3.15%

EBITD / Share (Annual)$-1.51

Operating Margin (Annual)-148.63%

P/CF (TTM)13.01x

EPS Basic Excl Extra (TTM)$-0.82

P/B Ratio (Annual)3.27x

Pretax Margin (TTM)-49.40%

Book Value / Share (Annual)$8.52

Price vs S&P 500 (13W)5.14%

Beta0.72x

P/FCF (Annual)12.80x

Revenue / Share (TTM)$1.61

ROE (TTM)-9.44%

52-Week Low$9.70

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.19est. -0.42

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
SEPNSepterna, Inc. Common Stock	D	A	B	$31.15
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Septerna Inc is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline addresses endocrinology, immunology/inflammation, and metabolic diseases, with lead candidates including SEP-786 (PTH1R), SEP-631 (MRGPRX2), and programs in GLP-1R, GIPR, GCGR, and TSHR. By enabling drug discovery against historically challenging GPCR targets, Septerna aims to address conditions with significant unmet medical needs.